Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 20 studies | 23% ± 8% | |
capillary endothelial cell | 9 studies | 22% ± 6% | |
endothelial cell of lymphatic vessel | 7 studies | 20% ± 3% | |
endothelial cell of vascular tree | 5 studies | 21% ± 2% | |
macrophage | 4 studies | 18% ± 3% | |
vein endothelial cell | 4 studies | 22% ± 6% | |
non-classical monocyte | 3 studies | 23% ± 7% | |
endothelial cell of artery | 3 studies | 20% ± 2% | |
epithelial cell | 3 studies | 29% ± 6% | |
dendritic cell | 3 studies | 26% ± 8% |
Insufficient scRNA-seq data for expression of PML at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 5521.66 | 1445 / 1445 | 100% | 49.99 | 183 / 183 |
ovary | 100% | 5382.12 | 180 / 180 | 100% | 47.10 | 430 / 430 |
skin | 100% | 6730.80 | 1809 / 1809 | 100% | 31.60 | 472 / 472 |
uterus | 100% | 9358.14 | 170 / 170 | 100% | 35.39 | 459 / 459 |
thymus | 100% | 7734.20 | 653 / 653 | 100% | 29.49 | 604 / 605 |
intestine | 100% | 6910.72 | 966 / 966 | 100% | 25.01 | 526 / 527 |
prostate | 100% | 6753.43 | 245 / 245 | 100% | 16.75 | 501 / 502 |
lung | 100% | 10593.49 | 578 / 578 | 99% | 29.28 | 1149 / 1155 |
breast | 100% | 11702.84 | 459 / 459 | 99% | 22.03 | 1110 / 1118 |
kidney | 100% | 4737.30 | 89 / 89 | 99% | 25.90 | 893 / 901 |
stomach | 100% | 4657.15 | 359 / 359 | 99% | 27.43 | 283 / 286 |
bladder | 100% | 6833.62 | 21 / 21 | 99% | 26.35 | 498 / 504 |
adrenal gland | 100% | 3906.85 | 257 / 258 | 94% | 12.69 | 217 / 230 |
brain | 81% | 1582.96 | 2145 / 2642 | 99% | 13.88 | 701 / 705 |
pancreas | 75% | 1412.30 | 245 / 328 | 99% | 31.24 | 176 / 178 |
liver | 88% | 1729.24 | 198 / 226 | 78% | 8.81 | 316 / 406 |
adipose | 100% | 11679.81 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 23.94 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 29.23 | 29 / 29 |
spleen | 100% | 7111.28 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 47.67 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 6.99 | 1 / 1 |
blood vessel | 100% | 6159.58 | 1334 / 1335 | 0% | 0 | 0 / 0 |
heart | 99% | 3368.73 | 853 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 96% | 4741.60 | 894 / 929 | 0% | 0 | 0 / 0 |
muscle | 88% | 1879.74 | 709 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_1901798 | Biological process | positive regulation of signal transduction by p53 class mediator |
GO_0097191 | Biological process | extrinsic apoptotic signaling pathway |
GO_0070059 | Biological process | intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress |
GO_0016925 | Biological process | protein sumoylation |
GO_0008285 | Biological process | negative regulation of cell population proliferation |
GO_0048146 | Biological process | positive regulation of fibroblast proliferation |
GO_2001238 | Biological process | positive regulation of extrinsic apoptotic signaling pathway |
GO_2000059 | Biological process | negative regulation of ubiquitin-dependent protein catabolic process |
GO_2000779 | Biological process | regulation of double-strand break repair |
GO_0090402 | Biological process | oncogene-induced cell senescence |
GO_0060444 | Biological process | branching involved in mammary gland duct morphogenesis |
GO_0045087 | Biological process | innate immune response |
GO_0010332 | Biological process | response to gamma radiation |
GO_0034097 | Biological process | response to cytokine |
GO_0010761 | Biological process | fibroblast migration |
GO_1990830 | Biological process | cellular response to leukemia inhibitory factor |
GO_0042771 | Biological process | intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator |
GO_0009411 | Biological process | response to UV |
GO_0010522 | Biological process | regulation of calcium ion transport into cytosol |
GO_0071353 | Biological process | cellular response to interleukin-4 |
GO_0030578 | Biological process | PML body organization |
GO_0032691 | Biological process | negative regulation of interleukin-1 beta production |
GO_0032922 | Biological process | circadian regulation of gene expression |
GO_0042752 | Biological process | regulation of circadian rhythm |
GO_0065003 | Biological process | protein-containing complex assembly |
GO_0016525 | Biological process | negative regulation of angiogenesis |
GO_2000758 | Biological process | positive regulation of peptidyl-lysine acetylation |
GO_0051457 | Biological process | maintenance of protein location in nucleus |
GO_0060395 | Biological process | SMAD protein signal transduction |
GO_0045165 | Biological process | cell fate commitment |
GO_0030099 | Biological process | myeloid cell differentiation |
GO_0032206 | Biological process | positive regulation of telomere maintenance |
GO_0001666 | Biological process | response to hypoxia |
GO_0008630 | Biological process | intrinsic apoptotic signaling pathway in response to DNA damage |
GO_0006606 | Biological process | protein import into nucleus |
GO_0006355 | Biological process | regulation of DNA-templated transcription |
GO_0006977 | Biological process | DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest |
GO_0043153 | Biological process | entrainment of circadian clock by photoperiod |
GO_0090398 | Biological process | cellular senescence |
GO_0044790 | Biological process | suppression of viral release by host |
GO_0008631 | Biological process | intrinsic apoptotic signaling pathway in response to oxidative stress |
GO_0048384 | Biological process | retinoic acid receptor signaling pathway |
GO_0030155 | Biological process | regulation of cell adhesion |
GO_0007179 | Biological process | transforming growth factor beta receptor signaling pathway |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0031503 | Biological process | protein-containing complex localization |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0032469 | Biological process | endoplasmic reticulum calcium ion homeostasis |
GO_0030308 | Biological process | negative regulation of cell growth |
GO_0005730 | Cellular component | nucleolus |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0031901 | Cellular component | early endosome membrane |
GO_0005654 | Cellular component | nucleoplasm |
GO_0016363 | Cellular component | nuclear matrix |
GO_0005829 | Cellular component | cytosol |
GO_0016605 | Cellular component | PML body |
GO_0005737 | Cellular component | cytoplasm |
GO_0000781 | Cellular component | chromosome, telomeric region |
GO_0005634 | Cellular component | nucleus |
GO_0003677 | Molecular function | DNA binding |
GO_0019789 | Molecular function | SUMO transferase activity |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0060090 | Molecular function | molecular adaptor activity |
GO_0046332 | Molecular function | SMAD binding |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0032183 | Molecular function | SUMO binding |
GO_0061659 | Molecular function | ubiquitin-like protein ligase activity |
GO_0008270 | Molecular function | zinc ion binding |
GO_0005515 | Molecular function | protein binding |
Gene name | PML |
Protein name | Protein PML (E3 SUMO-protein ligase PML) (EC 2.3.2.-) (Promyelocytic leukemia protein) (RING finger protein 71) (RING-type E3 SUMO transferase PML) (Tripartite motif-containing protein 19) (TRIM19) PML nuclear body scaffold PML protein Promyelocytic leukemia gene protein |
Synonyms | TRIM19 MYL PP8675 RNF71 |
Description | FUNCTION: Functions via its association with PML-nuclear bodies (PML-NBs) in a wide range of important cellular processes, including tumor suppression, transcriptional regulation, apoptosis, senescence, DNA damage response, and viral defense mechanisms. Acts as the scaffold of PML-NBs allowing other proteins to shuttle in and out, a process which is regulated by SUMO-mediated modifications and interactions. Inhibits EIF4E-mediated mRNA nuclear export by reducing EIF4E affinity for the 5' 7-methylguanosine (m7G) cap of target mRNAs . Isoform PML-4 has a multifaceted role in the regulation of apoptosis and growth suppression: activates RB1 and inhibits AKT1 via interactions with PP1 and PP2A phosphatases respectively, negatively affects the PI3K pathway by inhibiting MTOR and activating PTEN, and positively regulates p53/TP53 by acting at different levels (by promoting its acetylation and phosphorylation and by inhibiting its MDM2-dependent degradation). Isoform PML-4 also: acts as a transcriptional repressor of TBX2 during cellular senescence and the repression is dependent on a functional RBL2/E2F4 repressor complex, regulates double-strand break repair in gamma-irradiation-induced DNA damage responses via its interaction with WRN, acts as a negative regulator of telomerase by interacting with TERT, and regulates PER2 nuclear localization and circadian function. Isoform PML-6 inhibits specifically the activity of the tetrameric form of PKM. The nuclear isoforms (isoform PML-1, isoform PML-2, isoform PML-3, isoform PML-4 and isoform PML-5) in concert with SATB1 are involved in local chromatin-loop remodeling and gene expression regulation at the MHC-I locus. Isoform PML-2 is required for efficient IFN-gamma induced MHC II gene transcription via regulation of CIITA. Cytoplasmic PML is involved in the regulation of the TGF-beta signaling pathway. PML also regulates transcription activity of ELF4 and can act as an important mediator for TNF-alpha- and IFN-alpha-mediated inhibition of endothelial cell network formation and migration. .; FUNCTION: Exhibits antiviral activity against both DNA and RNA viruses. The antiviral activity can involve one or several isoform(s) and can be enhanced by the permanent PML-NB-associated protein DAXX or by the recruitment of p53/TP53 within these structures. Isoform PML-4 restricts varicella zoster virus (VZV) via sequestration of virion capsids in PML-NBs thereby preventing their nuclear egress and inhibiting formation of infectious virus particles. The sumoylated isoform PML-4 restricts rabies virus by inhibiting viral mRNA and protein synthesis. The cytoplasmic isoform PML-14 can restrict herpes simplex virus-1 (HHV-1) replication by sequestering the viral E3 ubiquitin-protein ligase ICP0 in the cytoplasm. Isoform PML-6 shows restriction activity towards human cytomegalovirus (HHV-5) and influenza A virus strains PR8(H1N1) and ST364(H3N2). Sumoylated isoform PML-4 and isoform PML-12 show antiviral activity against encephalomyocarditis virus (EMCV) by promoting nuclear sequestration of viral polymerase (P3D-POL) within PML NBs. Isoform PML-3 exhibits antiviral activity against poliovirus by inducing apoptosis in infected cells through the recruitment and the activation of p53/TP53 in the PML-NBs. Isoform PML-3 represses human foamy virus (HFV) transcription by complexing the HFV transactivator, bel1/tas, preventing its binding to viral DNA. PML may positively regulate infectious hepatitis C viral (HCV) production and isoform PML-2 may enhance adenovirus transcription. Functions as an E3 SUMO-protein ligase that sumoylates (HHV-5) immediate early protein IE1, thereby participating in the antiviral response . Isoforms PML-3 and PML-6 display the highest levels of sumoylation activity . . |
Accessions | ENST00000562086.1 ENST00000354026.10 [P29590-13] ENST00000569477.5 [P29590-9] ENST00000564428.5 [P29590-12] ENST00000566068.1 H3BVD2 H3BUJ5 ENST00000435786.6 [P29590-2] ENST00000565239.5 ENST00000268059.10 [P29590-8] ENST00000565898.5 [P29590-11] Q9UE85 H3BT29 H3BRN3 ENST00000567543.5 [P29590-14] ENST00000395135.7 [P29590-5] ENST00000436891.7 [P29590-4] ENST00000268058.8 [P29590-1] ENST00000563500.5 P29590 ENST00000359928.8 [P29590-14] A4VCI9 ENST00000567606.5 ENST00000395132.6 [P29590-10] H3BT57 ENST00000569965.5 [P29590-4] |